<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362180</url>
  </required_header>
  <id_info>
    <org_study_id>301012-CS10</org_study_id>
    <secondary_id>2005-005783-90</secondary_id>
    <nct_id>NCT00362180</nct_id>
  </id_info>
  <brief_title>Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Apolipoprotein B(ApoB) Reduction by ISIS 301012 on Liver Triglyceride Content in Subjects With Varying Degrees of Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kastle Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kastle Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver
      triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic
      steatosis. In order to enroll subject groups with varying degrees of risk, the study has
      included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been
      accomplished with protocol amendments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, placebo-controlled study to measure the effect of
      treatment with mipomersen on liver triglyceride (TG) content in patients with varying degrees
      of hyperlipidemia and risk for hepatic steatosis.

      The original study design included 4 cohorts (Cohorts A through D). Subsequent protocol
      amendments added 3 cohorts (Cohorts E, F, and G) to the study, truncated the enrollment of
      Cohort D, and eliminated Cohorts B and C. The study consisted of up to a 3-week screening
      period; a 4-week (Cohorts A and D), 13-week (Cohort E), or 52-week (Cohort G) treatment
      period; and a 20-week post-treatment follow-up period. Cohort F was an observational cohort,
      and therefore, was not treated with study drug. Patients in this cohort underwent a 15-week
      Magnetic resonance spectroscopy (MRS) and ultrasound evaluation period.

      The study cohorts are:

      Cohort A: Healthy volunteers with LDL-C &lt;140 mg/dL (3.6 mmol/L), serum TG &lt;200 mg/dL (2.3
      mmol/L), hemoglobin A1c (HbA1c) &lt;6.0%, and hepatic TG content &lt;5% (as measured by MRS at
      screening). Patients were randomized to mipomersen 200 mg or placebo and treated for 4 weeks.

      Cohorts B+C were eliminated in a protocol amendment prior to enrolling any patients and are
      not discussed further.

      Cohort D: In an amendment to the protocol, Cohort D was closed to enrollment. One patient had
      already been enrolled in the study prior to the amendment. The patient enrolled in this
      cohort had impaired fasting glucose (defined as fasting blood glucose &gt;6 mmol/L and &lt;7
      mmol/L) and mixed dyslipidemia (LDL-C &lt;215 mg/dL [5.6 mmol/L] and serum TG &gt;200 mg/dL [2.3
      mmol/L]). The patient was treated with mipomersen 200 mg for 4 weeks.

      Cohort E: Patients with uncomplicated heterozygous familial hypercholesterolemia (HeFH)
      (Alanine aminotransferase (ALT) ≤1.5 * upper limit of normal Upper limit of normal (ULN), no
      evidence of insulin resistance or metabolic syndrome, and hepatic TG content &lt;5% by MRS at
      screening). Patients were to remain on their baseline statin ± ezetimibe regimen but were to
      wash out from other lipid-lowering agents (e.g., fenofibrate, non-dietary omega-3 fatty
      acids, and niacin) at least 8 weeks prior to the MRS at screening. Patients were randomized
      to either mipomersen 200 mg or placebo for 13 weeks.

      Cohort F: Patients with familial hypobetalipoproteinemia (FHBL) (a documented APOB gene
      mutation that results in the expression of a truncated form of apo B). Patients in this
      cohort were evaluated by MRS, ultrasound, and laboratory tests; however, they were not
      treated with mipomersen or placebo.

      Cohort G: Patients with well-controlled type 2 diabetes mellitus (HbA1c ≤8.0%),
      hypercholesterolemia (LDL-C &gt;100 mg/dL (2.59 mmol/L), and normal serum TG levels (≤200 mg/dL
      [2.26 mmol/L]). Patients were to have been on a stable dose of antidiabetic and
      lipid-lowering medications &gt;3 months prior to screening and were expected to remain stable
      for the duration of the study. Patients were randomized to either mipomersen 200 mg or
      placebo for 26 weeks, followed by 26 additional weeks of mipomersen 200 mg. Recruiting
      difficulties caused this cohort to close early.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Liver Triglyceride (TG) Content As Measured by Magnetic Resonance Spectroscopy (MRS)</measure>
    <time_frame>Baseline, Day 26, Day 99</time_frame>
    <description>Localized proton MRS was used to quantify liver TG concentration. All MRS imaging of the liver was performed using the same 1.5T scanner. The instructions were to cover the entire liver (from just above the dome to just below the inferior tip) using a qualified imaging technique (Yokoo, 2009, Radiology). Liver fat quantification was performed by determining the liver fat fraction (%) derived from MRS using selected Regions of Interest (ROI). The analyst typically looked for the branching of the right portal vein and mapped slices from one scan to the next. There were typically 2 ROIs in the right lobe and 1 in the left lobe. Magnetic resonance spectroscopy imaging ROIs between different scans were selected using anatomical landmarks for both time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Apolipoprotein B</measure>
    <time_frame>Baseline</time_frame>
    <description>Samples were taken following an overnight fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein B From Baseline to Day 99</measure>
    <time_frame>Day 26 and Day 99</time_frame>
    <description>Samples were taken following an overnight fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Low-Density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline</time_frame>
    <description>Samples were taken following overnight fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low-Density Lipoprotein Cholesterol From Baseline to Day 99</measure>
    <time_frame>Day 26 and Day 99</time_frame>
    <description>Samples were taken following an overnight fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Total Cholesterol</measure>
    <time_frame>Baseline</time_frame>
    <description>Samples were taken following an overnight fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol From Baseline to Day 99</measure>
    <time_frame>Day 26 and Day 99</time_frame>
    <description>Samples were taken following an overnight fast.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Lipid Metabolism, Inborn Errors</condition>
  <condition>Hyperlipidemias</condition>
  <condition>Metabolic Diseases</condition>
  <condition>Hypolipoproteinemia</condition>
  <condition>Hypolipoproteinemias</condition>
  <condition>Hypobetalipoproteinemias</condition>
  <condition>Metabolism, Inborn Errors</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Infant, Newborn, Diseases</condition>
  <condition>Congenital Abnormalities</condition>
  <condition>Metabolic Disorder</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Dyslipidemias</condition>
  <condition>Lipid Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Cohort A: mipomersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: mipomersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: mipomersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F: no intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G: mipomersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G: placebo followed by mipomersen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mipomersen</intervention_name>
    <description>200 mg subcutaneous injections</description>
    <arm_group_label>Cohort A: mipomersen</arm_group_label>
    <arm_group_label>Cohort D: mipomersen</arm_group_label>
    <arm_group_label>Cohort E: mipomersen</arm_group_label>
    <arm_group_label>Cohort G: mipomersen</arm_group_label>
    <arm_group_label>Cohort G: placebo followed by mipomersen</arm_group_label>
    <other_name>ISIS 301012</other_name>
    <other_name>mipomersen sodium</other_name>
    <other_name>Kynamro™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneous injections</description>
    <arm_group_label>Cohort A: placebo</arm_group_label>
    <arm_group_label>Cohort D: placebo</arm_group_label>
    <arm_group_label>Cohort E: placebo</arm_group_label>
    <arm_group_label>Cohort G: placebo followed by mipomersen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group A - are healthy subjects

          -  Group D - has impaired fasting glucose and mixed dyslipidemia

          -  Group E - has a diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH) and on
             stable lipid-lowering therapy for 3 months

          -  Group F - has a diagnosis of Familial Hypobetalipoproteinemia (FHBL)

          -  Group G - has a diagnosis of Diabetes and hypercholesterolemia

        Exclusion Criteria:

          -  Medical, surgical, laboratory or other conditions which in the judgment of the
             Physician Investigator would make the subject unsuitable for enrollment, or
             potentially interfere with subject participation or completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJ, Trip MD, Stroes ES. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010 May;51(5):1057-62. doi: 10.1194/jlr.M002915. Epub 2009 Dec 14.</citation>
    <PMID>20008831</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2006</study_first_submitted>
  <study_first_submitted_qc>August 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2006</study_first_posted>
  <results_first_submitted>February 25, 2013</results_first_submitted>
  <results_first_submitted_qc>June 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2015</results_first_posted>
  <disposition_first_submitted>September 19, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 19, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 26, 2012</disposition_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL-cholesterol</keyword>
  <keyword>apoB-100</keyword>
  <keyword>apoB-48</keyword>
  <keyword>triglyceride</keyword>
  <keyword>HeFH</keyword>
  <keyword>FHBL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Hypobetalipoproteinemias</mesh_term>
    <mesh_term>Hypolipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mipomersen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort A: Mipomersen</title>
          <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Cohort A: Placebo</title>
          <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Cohort D: Mipomersen</title>
          <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Cohort D: Placebo</title>
          <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Cohort E: Placebo</title>
          <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Cohort E: Mipomersen</title>
          <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Cohort F: no Study Intervention</title>
          <description>A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Cohort G: Mipomersen</title>
          <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
        </group>
        <group group_id="P9">
          <title>Cohort G: Placebo Followed by Mipomersen</title>
          <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treated Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>20 Week Safety Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="0">This observational cohort did not include a safety follow-up period.</participants>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A: Mipomersen</title>
          <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Cohort A: Placebo</title>
          <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Cohort D: Mipomersen</title>
          <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Cohort D: Placebo</title>
          <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Cohort E: Placebo</title>
          <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Cohort E: Mipomersen</title>
          <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Cohort F: no Study Intervention</title>
          <description>A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Cohort G: Mipomersen</title>
          <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Cohort G: Placebo Followed by Mipomersen</title>
          <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="1"/>
            <count group_id="B10" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" lower_limit="57" upper_limit="65"/>
                    <measurement group_id="B2" value="40.5" lower_limit="24" upper_limit="57"/>
                    <measurement group_id="B3" value="59.0" lower_limit="59" upper_limit="59"/>
                    <measurement group_id="B5" value="46.0" lower_limit="28" upper_limit="59"/>
                    <measurement group_id="B6" value="50.0" lower_limit="23" upper_limit="63"/>
                    <measurement group_id="B7" value="49.5" lower_limit="29" upper_limit="71"/>
                    <measurement group_id="B8" value="62.0" lower_limit="49" upper_limit="64"/>
                    <measurement group_id="B9" value="58.0" lower_limit="58" upper_limit="58"/>
                    <measurement group_id="B10" value="53.5" lower_limit="23" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Liver Triglyceride (TG) Content As Measured by Magnetic Resonance Spectroscopy (MRS)</title>
        <description>Localized proton MRS was used to quantify liver TG concentration. All MRS imaging of the liver was performed using the same 1.5T scanner. The instructions were to cover the entire liver (from just above the dome to just below the inferior tip) using a qualified imaging technique (Yokoo, 2009, Radiology). Liver fat quantification was performed by determining the liver fat fraction (%) derived from MRS using selected Regions of Interest (ROI). The analyst typically looked for the branching of the right portal vein and mapped slices from one scan to the next. There were typically 2 ROIs in the right lobe and 1 in the left lobe. Magnetic resonance spectroscopy imaging ROIs between different scans were selected using anatomical landmarks for both time points.</description>
        <time_frame>Baseline, Day 26, Day 99</time_frame>
        <population>Full analysis set. In Cohort E: Placebo, Day 99 N=11 instead of 10 because participant did not have a post treatment MRS by Day 26.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Placebo</title>
            <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Mipomersen</title>
            <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort D</title>
            <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort E: Placebo</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort E: Mipomersen</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort F: no Study Intervention</title>
            <description>Participants with a diagnosis of Familial Hypobetalipoproteinemia (FHBL) and were not treated with mipomersen or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Cohort G: Placebo Followed by Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Cohort G: Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Liver Triglyceride (TG) Content As Measured by Magnetic Resonance Spectroscopy (MRS)</title>
          <description>Localized proton MRS was used to quantify liver TG concentration. All MRS imaging of the liver was performed using the same 1.5T scanner. The instructions were to cover the entire liver (from just above the dome to just below the inferior tip) using a qualified imaging technique (Yokoo, 2009, Radiology). Liver fat quantification was performed by determining the liver fat fraction (%) derived from MRS using selected Regions of Interest (ROI). The analyst typically looked for the branching of the right portal vein and mapped slices from one scan to the next. There were typically 2 ROIs in the right lobe and 1 in the left lobe. Magnetic resonance spectroscopy imaging ROIs between different scans were selected using anatomical landmarks for both time points.</description>
          <population>Full analysis set. In Cohort E: Placebo, Day 99 N=11 instead of 10 because participant did not have a post treatment MRS by Day 26.</population>
          <units>percentage of total liver content</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Cohort E: Placebo n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="0.3"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.5" upper_limit="1.8"/>
                    <measurement group_id="O3" value="6.4" lower_limit="6.4" upper_limit="6.4"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.2" upper_limit="3.2"/>
                    <measurement group_id="O5" value="1.1" lower_limit="0.3" upper_limit="3.8"/>
                    <measurement group_id="O6" value="21.4" lower_limit="13.2" upper_limit="30.1"/>
                    <measurement group_id="O7" value="2.6" lower_limit="2.6" upper_limit="2.6"/>
                    <measurement group_id="O8" value="2.5" lower_limit="1.7" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26 (Cohort E: Placebo n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="4.45" lower_limit="4.45" upper_limit="4.45"/>
                    <measurement group_id="O4" value="0.1" lower_limit="-0.4" upper_limit="0.8"/>
                    <measurement group_id="O5" value="0.1" lower_limit="-2.5" upper_limit="0.5"/>
                    <measurement group_id="O6" value="-1.2" lower_limit="-2.6" upper_limit="4.3"/>
                    <measurement group_id="O7" value="NA">Liver TG not collected at day 26 as per protocol</measurement>
                    <measurement group_id="O8" value="NA">Liver TG not collected at day 26 as per protocol</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99 (Cohort E: Placebo n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Liver TG not collected at day 99 as per protocol</measurement>
                    <measurement group_id="O2" value="NA">Liver TG not collected at day 99 as per protocol</measurement>
                    <measurement group_id="O3" value="NA">Only 1 patient was enrolled in cohort D, there was no day 99 visit for cohort D</measurement>
                    <measurement group_id="O4" value="-0.0" lower_limit="-1.5" upper_limit="1.3"/>
                    <measurement group_id="O5" value="0.4" lower_limit="-1.7" upper_limit="5.1"/>
                    <measurement group_id="O6" value="0.8" lower_limit="-2.0" upper_limit="4.3"/>
                    <measurement group_id="O7" value="-1.0" lower_limit="-1.0" upper_limit="-1.0"/>
                    <measurement group_id="O8" value="7.8" lower_limit="1.1" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The p-value is a comparison between the placebo group and the mipomersen group in Cohort E as a change from Baseline to Day 26.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7244</p_value>
            <method>exact Wilcoxon Rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The p-value is a comparison between the placebo group and the mipomersen group in Cohort E as a change from Baseline to Day 99.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0513</p_value>
            <method>exact Wilcoxon Rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Apolipoprotein B</title>
        <description>Samples were taken following an overnight fast.</description>
        <time_frame>Baseline</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Placebo</title>
            <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Mipomersen</title>
            <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort D</title>
            <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort E: Placebo</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort E: Mipomersen</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort F: no Study Intervention</title>
            <description>Participants with a diagnosis of Familial Hypobetalipoproteinemia (FHBL) and were not treated with mipomersen or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Cohort G: Placebo Followed by Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Cohort G: Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Apolipoprotein B</title>
          <description>Samples were taken following an overnight fast.</description>
          <population>Full analysis set</population>
          <units>mg/wk</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="70" upper_limit="102"/>
                    <measurement group_id="O2" value="100.5" lower_limit="76.5" upper_limit="102.0"/>
                    <measurement group_id="O3" value="155" lower_limit="155" upper_limit="155"/>
                    <measurement group_id="O4" value="122.0" lower_limit="106.0" upper_limit="148.0"/>
                    <measurement group_id="O5" value="126.5" lower_limit="109.0" upper_limit="153.0"/>
                    <measurement group_id="O6" value="31.5" lower_limit="28.0" upper_limit="41.0"/>
                    <measurement group_id="O7" value="120.0" lower_limit="120.0" upper_limit="120.0"/>
                    <measurement group_id="O8" value="113.0" lower_limit="90.0" upper_limit="132.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein B From Baseline to Day 99</title>
        <description>Samples were taken following an overnight fast.</description>
        <time_frame>Day 26 and Day 99</time_frame>
        <population>Full analysis set with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Placebo</title>
            <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Mipomersen</title>
            <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort D</title>
            <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort E: Placebo</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort E: Mipomersen</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort F: No Study Intervention</title>
            <description>A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Cohort G: Placebo Followed by Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Cohort G: Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein B From Baseline to Day 99</title>
          <description>Samples were taken following an overnight fast.</description>
          <population>Full analysis set with last observation carried forward.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-8.6" upper_limit="2.0"/>
                    <measurement group_id="O2" value="-20.8" lower_limit="-24.8" upper_limit="-13.6"/>
                    <measurement group_id="O3" value="-41.6149" lower_limit="-41.6149" upper_limit="-41.6149"/>
                    <measurement group_id="O4" value="-1.1" lower_limit="-1.8" upper_limit="0.0"/>
                    <measurement group_id="O5" value="-1.8" lower_limit="-16.3" upper_limit="13.4"/>
                    <measurement group_id="O6" value="3.6" lower_limit="-4.9" upper_limit="14.3"/>
                    <measurement group_id="O7" value="NA">Apolipoprotein B was not collected at day 26 as per protocol</measurement>
                    <measurement group_id="O8" value="NA">Apolipoprotein B was not collected at day 26 as per protocol</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Apolipoprotein B was not collected at day 99 as per protocol</measurement>
                    <measurement group_id="O2" value="NA">Apolipoprotein B was not collected at day 99 as per protocol</measurement>
                    <measurement group_id="O3" value="NA">Only 1 patient was enrolled in cohort D, there was no day 99 visit for cohort D</measurement>
                    <measurement group_id="O4" value="6.0" lower_limit="-2.7" upper_limit="15.3"/>
                    <measurement group_id="O5" value="-16.3" lower_limit="-29.3" upper_limit="-5.6"/>
                    <measurement group_id="O6" value="4.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O7" value="-25.8" lower_limit="-25.8" upper_limit="-25.8"/>
                    <measurement group_id="O8" value="-44.2" lower_limit="-55.6" upper_limit="-18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Low-Density Lipoprotein Cholesterol</title>
        <description>Samples were taken following overnight fast.</description>
        <time_frame>Baseline</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Placebo</title>
            <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Mipomersen</title>
            <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort D</title>
            <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort E: Placebo</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort E: Mipomersen</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort F: No Study Intervention</title>
            <description>A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Cohort G: Placebo Followed by Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Cohort G: Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Low-Density Lipoprotein Cholesterol</title>
          <description>Samples were taken following overnight fast.</description>
          <population>Full analysis set</population>
          <units>mg/wk</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.5" lower_limit="77.0" upper_limit="130.0"/>
                    <measurement group_id="O2" value="126.0" lower_limit="93.0" upper_limit="139.5"/>
                    <measurement group_id="O3" value="156.0" lower_limit="156.0" upper_limit="156.0"/>
                    <measurement group_id="O4" value="148.0" lower_limit="131.0" upper_limit="182.0"/>
                    <measurement group_id="O5" value="151.5" lower_limit="127.0" upper_limit="161.0"/>
                    <measurement group_id="O6" value="41.5" lower_limit="37.0" upper_limit="55.0"/>
                    <measurement group_id="O7" value="147.0" lower_limit="147.0" upper_limit="147.0"/>
                    <measurement group_id="O8" value="121.0" lower_limit="94.0" upper_limit="131.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low-Density Lipoprotein Cholesterol From Baseline to Day 99</title>
        <description>Samples were taken following an overnight fast.</description>
        <time_frame>Day 26 and Day 99</time_frame>
        <population>Full analysis set with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Placebo</title>
            <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Mipomersen</title>
            <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort D: Mipomersen</title>
            <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort E: Placebo</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort E: Mipomersen</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort F: No Study Intervention</title>
            <description>A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Cohort G: Placebo Follwed by Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Cohort G: Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low-Density Lipoprotein Cholesterol From Baseline to Day 99</title>
          <description>Samples were taken following an overnight fast.</description>
          <population>Full analysis set with last observation carried forward.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-11.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-14.3" lower_limit="-20.5" upper_limit="-6.0"/>
                    <measurement group_id="O3" value="-41.7143" lower_limit="-41.7143" upper_limit="-41.7143"/>
                    <measurement group_id="O4" value="-2.7" lower_limit="-5.0" upper_limit="2.4"/>
                    <measurement group_id="O5" value="-5.4" lower_limit="-20.9" upper_limit="11.4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-4.9" upper_limit="8.0"/>
                    <measurement group_id="O7" value="NA">Low-density lipoprotein was not collected at day 26 as per protocol</measurement>
                    <measurement group_id="O8" value="NA">Low-density lipoprotein was not collected at day 26 as per protocol</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Low-density lipoprotein was not collected at day 99 as per protocol</measurement>
                    <measurement group_id="O2" value="NA">Low-density lipoprotein was not collected at day 99 as per protocol</measurement>
                    <measurement group_id="O3" value="NA">Only 1 patient was enrolled in cohort D, there was no day 99 visit for cohort D</measurement>
                    <measurement group_id="O4" value="0.7" lower_limit="-9.8" upper_limit="13.5"/>
                    <measurement group_id="O5" value="-15.9" lower_limit="-36.1" upper_limit="-12.4"/>
                    <measurement group_id="O6" value="2.6" lower_limit="-5.1" upper_limit="9.0"/>
                    <measurement group_id="O7" value="-19.0" lower_limit="-19.0" upper_limit="-19.0"/>
                    <measurement group_id="O8" value="-33.9" lower_limit="-63.8" upper_limit="-18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Total Cholesterol</title>
        <description>Samples were taken following an overnight fast.</description>
        <time_frame>Baseline</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Placebo</title>
            <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Mipomersen</title>
            <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort D</title>
            <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort E: Placebo</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort E: Mipomersen</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort F: No Study Intervention</title>
            <description>A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Cohort G: Placebo Followed by Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Cohort G: Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Total Cholesterol</title>
          <description>Samples were taken following an overnight fast.</description>
          <population>Full analysis set</population>
          <units>mg/wk</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.0" lower_limit="165.0" upper_limit="237.0"/>
                    <measurement group_id="O2" value="207.0" lower_limit="176.0" upper_limit="213.0"/>
                    <measurement group_id="O3" value="263.0" lower_limit="263.0" upper_limit="263.0"/>
                    <measurement group_id="O4" value="208.0" lower_limit="191.0" upper_limit="245.0"/>
                    <measurement group_id="O5" value="220.5" lower_limit="189.0" upper_limit="248.0"/>
                    <measurement group_id="O6" value="107.0" lower_limit="93.0" upper_limit="115.0"/>
                    <measurement group_id="O7" value="231.0" lower_limit="231.0" upper_limit="231.0"/>
                    <measurement group_id="O8" value="199.0" lower_limit="171.0" upper_limit="208.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol From Baseline to Day 99</title>
        <description>Samples were taken following an overnight fast.</description>
        <time_frame>Day 26 and Day 99</time_frame>
        <population>Full analysis set with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Placebo</title>
            <description>Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Mipomersen</title>
            <description>Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Cohort D: Mipomersen</title>
            <description>Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Cohort E: Mipomersen</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Cohort E: Placebo</title>
            <description>Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Cohort F: No Study Intervention</title>
            <description>A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Cohort G: Placebo Follwed by Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Cohort G: Mipomersen</title>
            <description>Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol From Baseline to Day 99</title>
          <description>Samples were taken following an overnight fast.</description>
          <population>Full analysis set with last observation carried forward.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-7.9" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-11.7" lower_limit="-12.5" upper_limit="-0.7"/>
                    <measurement group_id="O3" value="-29.5374" lower_limit="-29.5374" upper_limit="-29.5374"/>
                    <measurement group_id="O4" value="-3.1" lower_limit="-16.9" upper_limit="10.1"/>
                    <measurement group_id="O5" value="0.1" lower_limit="-2.1" upper_limit="3.0"/>
                    <measurement group_id="O6" value="1.4" lower_limit="0.0" upper_limit="2.7"/>
                    <measurement group_id="O7" value="NA">Total cholesterol was not collected at day 26 as per protocol</measurement>
                    <measurement group_id="O8" value="NA">Total cholesterol was not collected at day 26 as per protocol</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Total cholesterol was not collected at day 99 as per protocol</measurement>
                    <measurement group_id="O2" value="NA">Total cholesterol was not collected at day 99 as per protocol</measurement>
                    <measurement group_id="O3" value="NA">Only 1 patient was enrolled in cohort D, there was no day 99 visit for cohort D</measurement>
                    <measurement group_id="O4" value="-11.8" lower_limit="-24.2" upper_limit="-9.7"/>
                    <measurement group_id="O5" value="-0.8" lower_limit="-8.9" upper_limit="12.7"/>
                    <measurement group_id="O6" value="-0.4" lower_limit="-6.9" upper_limit="4.3"/>
                    <measurement group_id="O7" value="-21.6" lower_limit="-33.9" upper_limit="-14.1"/>
                    <measurement group_id="O8" value="-21.6" lower_limit="-33.9" upper_limit="-14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (&quot;number of affected participants&quot;) of both adverse event tables.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Mipomersen</title>
          <description>Mipomersen</description>
        </group>
        <group group_id="E3">
          <title>Not Treated</title>
          <description>Not Treated</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal septum disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eustachian tube disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diaphragmatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal septum disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI gives Sponsor a draft 90 days before publication. Sponsor has the right to demand that confidential information be removed, and can defer publication another 180 days upon notifying PI that it will file a patent application on inventions contained in the draft.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations to this study are 1) post-hoc amendments that caused early termination of cohorts and limited the accomplishment of study objectives and 2) post-hoc amendments which added cohorts into the study that were not previously specified.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christopher Bryant, Ph.D.</name_or_title>
      <organization>Kastle Therapeutics, LLC</organization>
      <phone>8152633913</phone>
      <email>cbryant@kastletx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

